Skip to content
Catalyst

L-arginineFinding

L-arginine decreases necrotising enterocolitis incidence

lowersVery limited evidenceFindingreplicated ×2

01 · The sentence it was drawn from

“There was a statistically significant reduction in the risk of developing NEC (any stage) in the arginine group compared with the placebo group (RR 0.24 [95% CI 0.10, 0.61], RD -0.21 [95% CI -0.32, -0.09]).”
Quoted verbatim from Arginine supplementation for prevention of necrotising enterocolitis in preterm infants.
This finding among the 8 findings on its endpoint

L-arginine

Necrotising enterocolitis incidence

lowers

Effect as reported

0.24risk ratio

CI 0.1 to 0.61

Who
preterm neonates given enteral or parenteral arginine supplementation vs placebo or no treatment, pooled from the single eligible trial identified by this review
Dose studied
not reported

Very limited evidencePMID 15495101 · 2004

02 · The study

Study
meta-analysis
Duration
not reported

Evidence, by strength

  • strong
  • moderate
  • limited
  • very limitedthis finding
  • insufficient

03 · The paper

The Cochrane database of systematic reviews
What else it reported1 finding · 1 compound · 1 endpoint

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M38THKV5T3TY274AD7FDCDZT